Twelve positions in a β-Lactamase that can expand its substrate spectrum with a single amino acid substitution

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Yi, Hyojeong ^a   Cho, Kwang Hwi ^b   Cho, Yun Sung ^b   Kim, Karan ^a   Nierman, William C ^c   Kim, Heenam Stanley ^a,c  

^a Korea University College of Medicine   (South Korea)

^b Soongsil University   (South Korea)

^c J CRAIG VENTER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFTAZIDIME;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BURKHOLDERIA; BURKHOLDERIA THAILANDENSIS; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROMOTER REGION; SIMULATION;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BURKHOLDERIA; CEFTAZIDIME; MICROBIAL SENSITIVITY TESTS;

BACTERIA (MICROORGANISMS); BURKHOLDERIA THAILANDENSIS;

EID: 84861308615     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037585     Document Type: Article

References (48)

1. Bush K, Fisher JF, (2011) Epidemiological Expansion, Structural Studies, and Clinical Challenges of New β-Lactamases from Gram-Negative Bacteria. Annual Review of Microbiology 65: 455-478.
2. Pitout JDD, Laupland KB, (2008) Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. The Lancet Infectious Diseases 8: 159-166.
3. Drawz SM, Bonomo RA, (2010) Three Decades of beta-Lactamase Inhibitors. Clin Microbiol Rev 23: 160-201.
4. Salverda ML, De Visser JA, Barlow M, (2010) Natural evolution of TEM-1 beta-lactamase: experimental reconstruction and clinical relevance. FEMS Microbiol Rev 34: 1015-1036.
5. Heritage J, M'Zali FH, Gascoyne-Binzi D, Hawkey PM, (1999) Evolution and spread of SHV extended-spectrum beta-lactamases in gram-negative bacteria. J Antimicrob Chemother 44: 309-318.
6. Bonnet R, (2004) Growing Group of Extended-Spectrum β-Lactamases: the CTX-M Enzymes. Antimicrob Agents Chemother 48: 1-14.
7. Brett PJ, DeShazer D, Woods DE, (1998) Burkholderia thailandensis sp. nov., a Burkholderia pseudomallei-like species. Int J Syst Bacteriol 48 Pt 1: 317-320.
8. D'Costa VM, King CE, Kalan L, Morar M, Sung WWL, et al. (2011) Antibiotic resistance is ancient. Nature 477: 457-461.
9. Poirel L, Rodriguez-Martinez J-M, Plesiat P, Nordmann P, (2009) Naturally Occurring Class A beta-Lactamases from the Burkholderia cepacia Complex. Antimicrob Agents Chemother 53: 876-882.
10. Sam IC, See KH, Puthucheary SD, (2009) Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei. J Clin Microbiol 47: 1556-1558.
11. Tribuddharat C, Moore RA, Baker P, Woods DE, (2003) Burkholderia pseudomallei class a beta-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition. Antimicrob Agents Chemother 47: 2082-2087.
12. Leitao JH, Sousa SA, Ferreira AS, Ramos CG, Silva IN, et al. (2010) Pathogenicity, virulence factors, and strategies to fight against Burkholderia cepacia complex pathogens and related species. Appl Microbiol Biotechnol 87: 31-40.
13. Wuthiekanun V, Peacock SJ, (2006) Management of melioidosis. Expert Rev Anti Infect Ther 4: 445-455.
14. Cheng AC, Currie BJ, (2005) Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 18: 383-416.
15. Song H, Hwang J, Yi H, Ulrich RL, Yu Y, et al. (2010) The Early Stage of Bacterial Genome-Reductive Evolution in the Host. PLoS Pathog 6: e1000922.
16. Sarovich DS, Price EP, Von Schulze AT, Cook JM, Mayo M, et al. (2012) Characterization of Ceftazidime Resistance Mechanisms in Clinical Isolates of Burkholderia pseudomallei from Australia. PLoS ONE 7: e30789.
17. Ambler RP, Coulson AF, Frere JM, Ghuysen JM, Joris B, et al. (1991) A standard numbering scheme for the class A beta-lactamases. Biochem J 276 (Pt 1): 269-270.
18. Jelsch C, Mourey L, Masson JM, Samama JP, (1993) Crystal structure of Escherichia coli TEM1 beta-lactamase at 1.8 A resolution. Proteins 16: 364-383.
19. Matagne A, Lamotte-Brasseur J, Frere JM, (1998) Catalytic properties of class A beta-lactamases: efficiency and diversity. Biochem J 330: 581-598.
20. Antunes NT, Frase H, Toth M, Mobashery S, Vakulenko SB, (2011) Resistance to the Third-Generation Cephalosporin Ceftazidime by a Deacylation-Deficient Mutant of the TEM β-Lactamase by the Uncommon Covalent-Trapping Mechanism. Biochemistry 50: 6387-6395.
21. Medeiros AA, (1997) Evolution and Dissemination of β-Lactamases Accelerated by Generations of β-Lactam Antibiotics. Clinical Infectious Diseases 24: S19-S45.
22. Hershberg R, Petrov DA, (2010) Evidence That Mutation Is Universally Biased towards AT in Bacteria. PLoS Genet 6: e1001115.
23. Rholl DA, Papp-Wallace KM, Tomaras AP, Vasil ML, Bonomo RA, et al. (2011) Molecular investigations of PenA-mediated beta-lactam resistance in Burkholderia pseudomallei. Frontiers in Microbiology 2.
24. Vakulenko SB, Taibi-Tronche P, Tóth M, Massova I, Lerner SA, et al. (1999) Effects on Substrate Profile by Mutational Substitutions at Positions 164 and 179 of the Class A TEMpUC19 β-Lactamase from Escherichia coli. Journal of Biological Chemistry 274: 23052-23060.
25. Ma L, Alba J, Chang F-Y, Ishiguro M, Yamaguchi K, et al. (2005) Novel SHV-Derived Extended-Spectrum β-Lactamase, SHV-57, That Confers Resistance to Ceftazidime but Not Cefazolin. Antimicrob Agents Chemother 49: 600-605.
26. Delmas J, Robin F, Carvalho F, Mongaret C, Bonnet R, (2006) Prediction of the Evolution of Ceftazidime Resistance in Extended-Spectrum β-Lactamase CTX-M-9. Antimicrob Agents Chemother 50: 731-738.
27. Chen Y, Shoichet B, Bonnet R, (2005) Structure, function, and inhibition along the reaction coordinate of CTX-M beta-lactamases. Journal of the American Chemical Society 127: 5423-5434.
28. Raquet X, Lamotte-Brasseur J, Fonz E, Goussard S, Courvalin P, et al. (1994) TEM beta-Lactamase Mutants Hydrolysing Third-generation Cephalosporins: A Kinetic and Molecular Modelling Analysis. Journal of Molecular Biology 244: 625-639.
29. Vakulenko SB, Toth M, Taibi P, Mobashery S, Lerner SA, (1995) Effects of Asp-179 mutations in TEMpUC19 beta-lactamase on susceptibility to beta-lactams. Antimicrob Agents Chemother 39: 1878-1880.
30. Wong W-T, Chan K-C, So P-K, Yap H-K, Chung W-H, et al. (2011) Increased Structural Flexibility at the Active Site of a Fluorophore-conjugated β-Lactamase Distinctively Impacts Its Binding toward Diverse Cephalosporin Antibiotics. Journal of Biological Chemistry 286: 31771-31780.
31. Delmas J, Leyssene D, Dubois D, Birck C, Vazeille E, et al. (2010) Structural Insights into Substrate Recognition and Product Expulsion in CTX-M Enzymes. Journal of Molecular Biology 400: 108-120.
32. Wang X, Minasov G, Shoichet BK, (2002) Evolution of an Antibiotic Resistance Enzyme Constrained by Stability and Activity Trade-offs. Journal of Molecular Biology 320: 85-95.
33. Ho PL, Cheung TK, Yam WC, Yuen KY, (2002) Characterization of a laboratory-generated variant of BPS beta-lactamase from Burkholderia pseudomallei that hydrolyses ceftazidime. J Antimicrob Chemother 50: 723-726.
34. Livermore DM, (2002) Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 34: 634-640.
35. Dance DAB, Wuthiekanun V, Chaowagul W, White NJ, (1989) The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. Journal of Antimicrobial Chemotherapy 24: 295-309.
36. Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD, (2004) Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J Antimicrob Chemother 54: 1134-1138.
37. Bonacorsi S, Fitoussi F, Lhopital S, Bingen E, (1999) Comparative In Vitro Activities of Meropenem, Imipenem, Temocillin, Piperacillin, and Ceftazidime in Combination with Tobramycin, Rifampin, or Ciprofloxacin against Burkholderia cepacia Isolates from Patients with Cystic Fibrosis. Antimicrob Agents Chemother 43: 213-217.
38. Saika T, Kobayashi I, Hasegawa M, Nishida M, (2002) Antimicrobial resistance and DNA-fingerprinting pattern of Burkholderia cepacia blood isolates. Journal of Infection and Chemotherapy 8: 341-344.
39. Ford PJ, Avison MB, (2004) Evolutionary mapping of the SHV beta-lactamase and evidence for two separate IS26-dependent blaSHV mobilization events from the Klebsiella pneumoniae chromosome. J Antimicrob Chemother 54: 69-75.
40. Kim HS, Yi H, Myung J, Piper KR, Farrand SK, (2008) Opine-Based Agrobacterium Competitiveness: Dual Expression Control of the Agrocinopine Catabolism (acc) Operon by Agrocinopines and Phosphate Levels. J Bacteriol 190: 3700-3711.
41. Joyce LF, Downes J, Stockman K, Andrew JH, (1992) Comparison of five methods, including the PDM Epsilometer test (E test), for antimicrobial susceptibility testing of Pseudomonas aeruginosa. J Clin Microbiol 30: 2709-2713.
42. Wiegand I, Hilpert K, Hancock REW, (2008) Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protocols 3: 163-175.
43. Keen NT, Tamaki S, Kobayashi D, Trollinger D, (1988) Improved broad-host-range plasmids for DNA cloning in Gram-negative bacteria. Gene 70: 191-197.
44. Thongdee M, Gallagher LA, Schell M, Dharakul T, Songsivilai S, et al. (2008) Targeted mutagenesis of Burkholderia thailandensis and Burkholderia pseudomallei through natural transformation of PCR fragments. Appl Environ Microbiol.
45. Simon R, Priefer U, Puhler A, (1983) Vector plasmids for in vivo and in vitro manipulations of gram-negative bacteria. Springer-Verlag KG, Berlin, Germany.
46. Sambrook J, F. Fritsch E, Maniatis T, (1989) Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
47. Friedrichs MS, Eastman P, Vaidyanathan V, Houston M, Legrand S, et al. (2009) Accelerating molecular dynamic simulation on graphics processing units. Journal of Computational Chemistry 30: 864-872.
48. Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, et al. (2006) CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Research 34: W116-W118.